Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
- 15 July 2004
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 2000
- https://doi.org/10.1200/jco.2004.22.14_suppl.2000
Abstract
2000 Background VEGF and HER1/EGFR play a pivotal role in many types of cancer. Bevacizumab (Avastin) is a recombinant, humanized anti-VEGF MAb, and erlotinib HCl (Tarceva) is a potent, reversible, and highly selective HER1/EGFR tyrosine-kinase inhibitor. Both have demonstrated antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). In addition, xenograft experiments performed in various tumor types suggest that growth inhibition using bevacizumab plus erlotinib (AT) is greater than with either agent alone. Therefore, there is compelling rationale for using AT as a therapy for NSCLC. Methods A multicenter, Phase I/II study examined AT in patients with either Stage IIIB/IV or recurrent NSCLC treated with at =1 prior chemotherapy regimen. In Phase I, erlotinib 150mg/day p.o. plus bevacizumab 15mg/kg i.v. every 21 days was established as the Phase II dose, although no true dose-limiting toxicities were observed. Phase II examined the efficacy and tolerability of the combina...Keywords
This publication has 0 references indexed in Scilit: